Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: Report of four cases

Cancer

Volumn 94, Issue 3, 2002, Pages 686-689

  Oh, William K ^a   George, Daniel J ^a   Kantoff, Philip W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Herbal therapy; PC SPES; Prostate carcinoma; Prostate specific antigen

Indexed keywords

ANDROGEN; DENDRANTEMA MORIFOLIUM EXTRACT; GANODERMA LUCIDUM EXTRACT; GLYCYRRHIZA URALENSIS EXTRACT; HERBACEOUS AGENT; ISATIS INDIGOTICA EXTRACT; PANAX PSEUDOGINSENG EXTRACT; PC SPES; PROSTATE SPECIFIC ANTIGEN; RABDOSIA RUBESCENS EXTRACT; SABAL EXTRACT; SCUTELLARIA BAICALENSIS EXTRACT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CASE REPORT; DRUG WITHDRAWAL; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE PROGRESSION; DRUGS, CHINESE HERBAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0036468724     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10269     Document Type: Article

References (10)

1. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology
2. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer
3. A prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
4. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer
5. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer
6. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist
7. Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome
8. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer
9. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm